AVITA Medical Secures Regulatory Approvals for RECELL GO in Australia, New Zealand
Event summary
- AVITA Medical received TGA certification in Australia and WAND listing in New Zealand for RECELL GO, its automated Spray-On Skin preparation system.
- Revolution Surgical, AVITA’s distribution partner, anticipates a commercial launch within the coming weeks.
- RECELL GO automates the preparation of RECELL Spray-On Skin, reducing operator variability and complexity.
- The system treats wounds up to 1,920 cm2 with a single preparation kit.
- RECELL was originally developed in Australia by Professor Fiona Wood and is now approved in the U.S., Europe, U.K., Australia, New Zealand, and Japan.
The big picture
The regulatory approvals for RECELL GO represent a significant step for AVITA Medical, solidifying its position in the acute wound care market. The move towards automation and standardization of skin cell preparation addresses a key pain point for clinicians, potentially improving patient outcomes and reducing costs. The partnership with Revolution Surgical will be crucial for driving adoption and market penetration in the Australian and New Zealand markets, which collectively represent a meaningful, albeit geographically concentrated, opportunity.
What we're watching
- Market Adoption
- The speed of commercial adoption in Australia and New Zealand will be a key indicator of RECELL GO’s value proposition and Revolution Surgical’s effectiveness as a distribution partner.
- Competitive Landscape
- How AVITA Medical’s standardized process and reduced operator burden will affect the competitive dynamics within the acute wound care market, particularly against alternative skin grafting methods, warrants close observation.
- Expansion Strategy
- The success in Australia and New Zealand will likely inform AVITA Medical’s strategy for expanding RECELL GO’s availability in other international markets.
